Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02915601 · ClinicalTrials.gov registry record · NA

Bicarbonate Administration in CKD

A NA study, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
109
Enrollment target

NCT02915601: Completed NA study, sponsored by University of Colorado, Denver.

NCT02915601 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 109 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02915601, a NA study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
109 participants
Enrollment target

Study Summary

Low serum bicarbonate levels, even within the normal laboratory range, are strongly associated with increased risks of hypertension, endothelial dysfunction, cardiovascular disease and death. The current proposal will investigate whether bicarbonate administration in patients with chronic kidney disease (CKD) will improve the health and function of arteries and reduce the size of the left ventricle of the heart. Overall, the proposed research will provide important new scientific evidence upon which physicians can base recommendations to patients with CKD to decrease the risk of developing cardiovascular diseases.

Interventions

  • DRUG Placebo
  • DRUG Sodium bicarbonate

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2017-01-15
Est. Completion 2022-05-19
Phase NA
University of Colorado, Denver

1,283 total trials

What the finished NCT02915601 record still lists

NCT02915601 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02915601 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02915601 about?

NCT02915601 is a clinical study titled "Bicarbonate Administration in CKD". Low serum bicarbonate levels, even within the normal laboratory range, are strongly associated with increased risks of hypertension, endothelial dysfunction, cardiovascular disease and death. The current proposal will investigate whether bicarbonate administration in patients with chronic kidney dis...

What is the current status of trial NCT02915601?

This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2017-01-15. Estimated completion is 2022-05-19.

What interventions are being tested in trial NCT02915601?

The interventions under investigation include: Placebo (DRUG), Sodium bicarbonate (DRUG).

Who is sponsoring clinical trial NCT02915601?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02915601's enrollment target sits among peer trials

109 825th of 2000 higher than 1,176 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02421380 · 109 participants · NA

    Characterization of Hyperpolarized Pyruvate MRI Reproducibility

  • NCT04526600 · 109 participants · NA

    Fidgeting and Attentional and Emotional Regulation in ADHD

  • NCT04835584 · 109 participants · Phase 1

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

  • NCT06626516 · 109 participants · Phase 1

    Tebentafusp-tebn With LDT in Metastatic UM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02915601, the US trial registry maintained by the National Library of Medicine. NCT02915601 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.